94424-50-7

Quinagolide is a potent and specific non-ergot dopamine D2 agonist launched in the Netherlands for the treatment of hyperprolactinemia. Quinagolide is effective in inhibiting prolactin secretion by human pituitary tumor and hyperprolactinemia in vitro and in viva A daily dose of as low as 60 pg is able to achieve a pronounced and prolonged suppressive effect on serum prolactin and growth hormone secretion. It is also effective in providing relief from associated effects such as infertility, galactorrhea, oligomenorrhea, amenorrhea, loss of IibMo and impotence. Compared with the most widely used antiprolactin, bromocriptine, quinagolide is more potent in vivo with a longer duration of action and fewer side effects. A recent study showed that acute administration of quinagolide suppresses growth hormone secretion in acromegalic patients and thus could serve as an alternative therapy in acromegaly.

Sandoz (Switzerland)

Quinagolide is a nonergot dopamine D2-receptor agonist. Quinagolide acts as an prolactin inhibitor.

Norprolac